Hap Trading, LLC Ascendis Pharma A/S Call Options Transaction History

Hap Trading, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $3.44 Million - $5.09 Million	40,000 New	40,000 $134 Million
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $3.48 Million - $4.62 Million	-35,000 Reduced 35.0%	65,000 $192,000
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $8.4 Million - $11 Million	100,000 New	100,000 $165,000
Q2 2022 Aug 12, 2022	SELL	$78.08 - $117.61 $788,608 - $1.19 Million	-10,100 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$102.18 - $135.75 $1.03 Million - $1.37 Million	10,100 New	10,100 $18,000
Q4 2020 Feb 16, 2021	SELL	$151.2 - $182.76 $4.54 Million - $5.48 Million	-30,000 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$110.87 - $156.01 $3.33 Million - $4.68 Million	30,000 New	30,000 $882,000

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.